Are you struggling with challenges in developing broad-spectrum anti-influenza therapies or confronting issues with viral resistance and antigenic drift? Creative Biolabs' IAV M2 Specific Neutra™ Antibody Products leverage advanced antibody engineering and structural virology insights to help you develop potent, cross-reactive neutralizing agents that target a highly conserved viral epitope.
The Influenza A Virus M2 (IAV M2) protein represents a critical, multifunctional component essential for viral infectivity and replication. As a type III transmembrane proton channel, it is incorporated in low copy numbers into the virion envelope and is abundantly expressed on the surface of infected cells. IAV M2 is a 97-amino acid protein encoded by segment 7 of the viral RNA genome. It is remarkably conserved across various human and avian influenza A strains, making it a prime target for universal vaccine and therapeutic development, unlike the highly variable hemagglutinin (HA) and neuraminidase (NA) proteins.
The functional unit is a homotetramer forming a pH-gated proton channel. Each monomer consists of a 24-residue N-terminal ectodomain (M2e), a single transmembrane helix, and a cytoplasmic C-terminal tail. The M2e region is exceptionally conserved and exposed, serving as the primary target for neutralizing antibodies. Structural studies reveal that the channel opens under acidic conditions (e.g., in the endosome), facilitating viral uncoating by allowing proton influx into the virion.
Fig.1 Three-dimensional representation of the influenza A M2 (AM2) ion channel structure.1
While adamantane drugs target the M2 transmembrane domain, widespread resistance has rendered them clinically obsolete due to point mutations. This underscores the need for alternative strategies targeting non-overlapping epitopes. M2 activity is also implicated in modulating autophagy pathways in host cells and can influence inflammasome activation, linking its function to viral pathogenesis and host immune response.
Fig.2 Schematic depiction illustrating the function of the M2 protein within the influenza A virus (IAV) life cycle.2
Influenza A virus causes seasonal epidemics and occasional pandemics, leading to significant morbidity and mortality worldwide. Complications include primary viral pneumonia, secondary bacterial pneumonia, and exacerbation of underlying cardiopulmonary diseases.
Antibodies targeting the conserved M2e ectodomain offer a promising strategy to overcome the limitations of strain-specific HA/NA-targeting approaches. These antibodies primarily mediate their protective effect via Fc receptor-dependent mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), to clear infected cells, as M2 is not a major target for classical virus-neutralization in vitro.
Anti-IAV M2 antibodies provide a crucial therapeutic avenue, especially against drug-resistant strains. In preclinical models, passive administration of M2e-specific monoclonal antibodies significantly reduces viral lung titers and improves survival rates, even when treatment is initiated post-infection. This approach complements antiviral drugs by leveraging the immune system to eliminate infected cells, offering a potent strategy for treating hospitalized patients with severe influenza.
Incorporating the M2e antigen into vaccine formulations is a leading strategy for developing a "universal" influenza vaccine. Anti-M2e antibodies elicited by such vaccines provide broad protection against diverse influenza A subtypes. Our high-affinity anti-M2e antibodies are indispensable tools for evaluating immunogenicity, mapping protective epitopes, and assessing the quality of M2e-directed immune responses in vaccine development pipelines.
Anti-IAV M2 antibodies enable the specific detection of influenza A infection across different strains in various immunoassays. They are valuable for serosurveillance studies to understand population exposure, for developing rapid point-of-care tests that differentiate influenza A from B, and for pathological staining to identify infected cells in tissue samples, aiding in both clinical diagnostics and research.
Creative Biolabs provides rigorously validated antibodies aimed at enhancing your influenza research and therapeutic initiatives:
Creative Biolabs is your trusted partner in virology and immunology research. We combine deep scientific knowledge of targets like IAV M2 with cutting-edge production platforms to provide researchers with reliable, high-performance tools. Our antibodies are engineered to deliver the specificity, affinity, and consistency required to translate discoveries into potential therapies. Contact our scientists today to discuss how our IAV M2 Specific Neutra™ Antibody Products can be tailored to your specific project needs.
References
Anti-IAV M2 Neutralizing Antibody (V3S-0522-YC3647) (CAT#: V3S-0522-YC3647)
Target: IAV M2
Host Species: Human
Target Species: Influenza A virus (IAV),
Application: ELISA,Neut,
Recombinant Mouse Anti-IAV M2 Antibody (V3S-0522-YC4766) (CAT#: V3S-0522-YC4766)
Target: IAV M2
Host Species: Mouse
Target Species: Influenza A virus (IAV),
Application: ELISA,
Recombinant Anti-IAV M2 Antibody (V3S-1022-YC1729) (CAT#: V3S-1022-YC1729)
Target: IAV M2
Host Species: Human
Target Species: Influenzavirus A (A/PR/8134 and A/HK/8/68),
Application: ELISA,